Cochrane Abstracts
GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs Unchanged
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"GenoType® MTBDRsl Assay for Resistance to Second‐line Anti‐tuberculosis Drugs Unchanged." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431351/all/Cilostazol_for_intermittent_claudication_New_search_for_studies_and_content_updated__no_change_to_conclusions_. Accessed 06 June 2023.
GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs Unchanged. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431351/all/Cilostazol_for_intermittent_claudication_New_search_for_studies_and_content_updated__no_change_to_conclusions_. Accessed June 6, 2023.
GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs Unchanged. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431351/all/Cilostazol_for_intermittent_claudication_New_search_for_studies_and_content_updated__no_change_to_conclusions_
GenoType® MTBDRsl Assay for Resistance to Second‐line Anti‐tuberculosis Drugs Unchanged [Internet]. In: Cochrane Abstracts. [cited 2023 June 06]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431351/all/Cilostazol_for_intermittent_claudication_New_search_for_studies_and_content_updated__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs Unchanged
ID - 431351
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431351/all/Cilostazol_for_intermittent_claudication_New_search_for_studies_and_content_updated__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -
